Panacea Pharmaceuticals, Inc., a company focused on developing therapeutic and diagnostic products for cancer, announced today that it has closed its Series C Private Placement raising approximately $7 million. Participants in the round included Mitsubishi Corporation Life Sciences Venture, Olympus, JSR, Shin-Etsu Chemical, Fuji Photo Film, Dai Nippon Printing, and Tokio Marine & Nichido Fire Insurance, among others.
INFO SOURCES
Panacea Pharmaceuticals, Inc.
FIRMS
Panacea Pharmaceuticals, Inc. is an emerging biopharmaceutical company focused on using functional genomics and proteomics to develop therapeutics and diagnostics for diseases with substantial unmet clinical need. The Company's product development focus is on novel proteins and biochemical pathways related to cellular regulation and cell cycle abnormalities in oncology as well as both acute and chronic neurodegenerative conditions such as hypoxia-induced cognitive impairment, Parkinson's disease, and Alzheimer's disease.
ADVISORS
The investments were secured through the assistance of the Cosmos Alliance
Supporting Material
